Helsinki, February 2026 — MVision AI has received market approval from the Therapeutic Goods Administration (TGA) in Australia for Workspace+, its AI-powered platform for radiotherapy. This approval enables the platform’s use in clinical settings across Australia.
Workspace+ brings contouring, synthetic imaging, dose prediction, and contour propagation into one secure environment. Clinics can run the four modules of Contour+, Dose+, Image+, and Adapt+ independently or as a unified suite, allowing teams to adapt the platform to their workflow requirements.
By automating repetitive tasks, Workspace+ enables more efficient radiotherapy preparation workflows and helps reduce manual effort. The platform supports clinicians in confident decision-making while leaving them in full control. It runs as a DICOM service and integrates directly with treatment planning systems and other DICOM-compliant systems.
“Receiving TGA approval for Workspace+ represents an important step in making intelligent, integrated planning tools more widely accessible,” said Mahmudul Hasan, Founder and CEO of MVision AI. “By bringing key planning capabilities together in a single secure platform, Workspace+ helps clinicians save time and promote consistency. This supports more standardised and reproducible workflows, allowing teams to focus more fully on patient care.”
This milestone further strengthens MVision AI’s presence in the Australian market, while also supporting the broader adoption of AI-powered planning workflows in routine radiotherapy practice across the region.
About MVision AI
Founded in 2017, MVision AI is a Finland-based health technology company developing AI-powered solutions to support radiotherapy treatment planning. Its products are used by leading cancer centres worldwide, helping to enable faster, more consistent, and patient-specific care across a broad range of clinical workflows.
MVision AI’s mission is to make same-day radiotherapy a reality by providing radiation oncology professionals with intelligent, clinically grounded tools. These tools promote standardisation and consistency, supporting confident clinical decision-making while keeping clinicians in full control.
*CE-marked (CE 2797) medical device under EU MDR 2017/745; this product is not available in all markets.
